Ferroptosis in cardiac hypertrophy and heart failure - 11/11/23
Abstract |
Heart failure has become a public health problem that we cannot avoid choosing to face in today's context. In the case of heart failure, pathological cardiac hypertrophy plays a major role because of its condition of absolute increase in ventricular mass under various stresses. Ferroptosis, it could be defined as regulatory mechanisms that regulate cell death in the absence of apoptosis in iron-dependent cells. This paper introduces various new research findings on the use of different regulatory mechanisms of cellular ferroptosis for the treatment of heart failure and cardiac hypertrophy, providing new therapeutic targets and research directions for clinical treatment. The role and mechanism of ferroptosis in the field of heart failure has been increasingly demonstrated, and the relationship between cardiac hypertrophy, which is one of the causes of heart failure, is also an area of research that we should focus on. In addition, the latest applications and progress of inducers and inhibitors of ferroptosis are reported in this paper, updating the breakthroughs in their fields.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Ferroptosis has many features that distinguish it from other RCDs. |
• | Ferroptosis may be a therapeutic target for heart failure and cardiac hypertrophy. |
• | Ferroptosis can be involved in treatment through a variety of mechanisms. |
• | Inducers and inhibitors of ferroptosis showed potential in curing cardiac disease. |
Abbreviations : LVEF, ROS, ACD, RCD, NCCD, RSL3, TFR1, STEAP, DMT1, FTL, FTH1, IRP, IREB2, ACO1, NCOA4, PROM2, PUFAs, LC-MS/MS, AA, AdA, PE, ACSL4, PUFA-CoA, LPCAT3, H2O2, LOXs, PEBP1, 15-HpETE-PE, NOXs, POR, SLC7A11, SLC3A2, OTUB1, CMEC, HSP90, Lamp-2a, CMA, UPS, PQQ, YAP, HFpEF, CoA, HFD, FUNDC1, SGLT2, VDACs, AIFM2, CMD, METTL3, m6, GCH1, DHODH, NRF2, AREs, ADR, AsIV, iPLA2β, Atg, NEFAs, PA, TRIM44, ncRNAs, circRNA, PCSK9, Siat7A, HIF-1ɑ, SQS, BBR, DFO, IOC, AMI, HOMO
Keywords : Heart failure, Cardiac hypertrophy, Ferroptosis, Regulation mechanism, Inducer and inhibitor
Plan
Vol 168
Article 115765- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?